用法用量 |
Thyroid cancer, differentiated(DTC)
PO 24 mg once daily until disease progression or unacceptable toxicity
Renal cell carcinoma, advanced(RCC)
PO 18 mg once daily (in combination with everolimus), continue until disease progression or unacceptable toxicity progression or unacceptable toxicity
Adjustment for Toxicity
[DTC]
First occurrence: Interrupt therapy until resolved to ≤ grade 1 or baseline, then resume dosing at 20 mg once daily.
Second occurrence (same or different toxicity): Interrupt therapy until resolved to ≤ grade 1 or baseline, then resume dosing at 14 mg once daily.
Third occurrence (same or different toxicity): Interrupt therapy until resolved to ≤ grade 1 or baseline, then resume dosing at 10 mg once daily.
[RCC]
First occurrence: Interrupt therapy until resolved to ≤ grade 1 or baseline, then resume dosing at 14 mg once daily.
Second occurrence (same or different toxicity): Interrupt therapy until resolved to ≤ grade 1 or baseline, then resume dosing at 10 mg once daily.
Third occurrence (same or different toxicity): Interrupt therapy until resolved to ≤ grade 1 or baseline, then resume dosing at 8 mg once daily.
Hepatocellular carcinoma(HCC), unresectable:
BW ≥60 kg:12 mg once daily
BW <60 kg:8 mg once daily |